Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation

Affiliations

• ¹ Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
• ² Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
• ³ Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. tooya-tky@umin.ac.jp.
• ⁴ Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
• ⁵ Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
• ⁶ Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
• ⁷ Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
• ⁸ Division of Clinical Precision Research Platform, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
• ⁹ Department of Cell Therapy and Transplantation Medicine, The University of Tokyo, Tokyo, Japan.